Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT06547944 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Newly Diagnosed

Interventions

DRUG: Zanubrutinib
DRUG: Lenalidomide
DRUG: Obinutuzumab

Sponsor

Institute of Hematology & Blood Diseases Hospital, China